Zhejiang Jolly Pharmaceutical Co Ltd (300181) — Net Asset Quality Index
Zhejiang Jolly Pharmaceutical Co Ltd (300181) has a Net Asset Quality Index of 65.5% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.33 Billion minus total liabilities of CN¥1.84 Billion yields net assets of CN¥3.49 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Zhejiang Jolly Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Jolly Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2007–2025)
This chart shows how Zhejiang Jolly Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 65.5%, representing net assets of CN¥3.49 Billion against total assets of CN¥5.33 Billion CNY. See Zhejiang Jolly Pharmaceutical Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Zhejiang Jolly Pharmaceutical Co Ltd (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Jolly Pharmaceutical Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 300181 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 68.8% | CN¥3.24 Billion | CN¥4.71 Billion | CN¥1.47 Billion | ▼ -1.8 pp |
| 2024 | 70.6% | CN¥2.82 Billion | CN¥3.99 Billion | CN¥1.17 Billion | ▼ -5.9 pp |
| 2023 | 76.5% | CN¥2.77 Billion | CN¥3.63 Billion | CN¥853.09 Million | ▲ +0.6 pp |
| 2022 | 75.8% | CN¥2.76 Billion | CN¥3.64 Billion | CN¥879.19 Million | ▲ +3.7 pp |
| 2021 | 72.2% | CN¥1.98 Billion | CN¥2.75 Billion | CN¥765.31 Million | ▲ +2.5 pp |
| 2020 | 69.6% | CN¥1.72 Billion | CN¥2.47 Billion | CN¥750.43 Million | ▲ +1.0 pp |
| 2019 | 68.7% | CN¥1.41 Billion | CN¥2.05 Billion | CN¥642.86 Million | ▲ +3.0 pp |
| 2018 | 65.6% | CN¥1.39 Billion | CN¥2.11 Billion | CN¥726.50 Million | ▼ -3.6 pp |
| 2017 | 69.2% | CN¥1.49 Billion | CN¥2.15 Billion | CN¥662.06 Million | ▼ -3.0 pp |
| 2016 | 72.2% | CN¥1.47 Billion | CN¥2.04 Billion | CN¥566.00 Million | ▼ -5.4 pp |
| 2015 | 77.6% | CN¥1.44 Billion | CN¥1.85 Billion | CN¥414.94 Million | ▲ +3.8 pp |
| 2014 | 73.8% | CN¥871.76 Million | CN¥1.18 Billion | CN¥309.75 Million | ▼ -8.2 pp |
| 2013 | 82.0% | CN¥772.52 Million | CN¥941.90 Million | CN¥169.38 Million | ▲ +0.3 pp |
| 2012 | 81.7% | CN¥705.92 Million | CN¥864.19 Million | CN¥158.27 Million | ▲ +0.6 pp |
| 2011 | 81.0% | CN¥683.92 Million | CN¥843.91 Million | CN¥159.99 Million | ▲ +21.6 pp |
| 2010 | 59.4% | CN¥207.17 Million | CN¥348.64 Million | CN¥141.47 Million | ▲ +3.8 pp |
| 2009 | 55.6% | CN¥165.70 Million | CN¥297.77 Million | CN¥132.07 Million | ▲ +2.4 pp |
| 2008 | 53.3% | CN¥149.11 Million | CN¥279.87 Million | CN¥130.76 Million | ▼ -4.2 pp |
| 2007 | 57.5% | CN¥144.47 Million | CN¥251.25 Million | CN¥106.79 Million | — |